Photocure ASA: Results for the second quarter and first half of 2020
Oslo, Norway, 18 August 2020: Photocure ASA (OSE:PHO) reported Hexvix[®]/Cysview[®] revenues of 53.5 million in the second quarter of 2020 (Q2 2019: NOK 52.1), corresponding to growth of three per cent, despite a significant Covid-19 impact in the beginning of the quarter in the U.S. market before a strong recovery towards the end of the period. The company has entered into an agreement with Ipsen Pharma SAS (Ipsen) for the return of Hexvix sales, marketing and distribution rights from the fourth quarter of 2020 and sees significant growth opportunities in Europe. The agreement is expected to